View in EDS

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E): Metastatic Non-Small Cell Lung Cancer.

Saved in:
Bibliographic Details
Title: Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E): Metastatic Non-Small Cell Lung Cancer.
Authors: Horn, L.1, Gettinger, S.2, Camidge, R.3, Smit, E.4, Janjigian, Y.5, Pao, W.1, Schnell, D.6, Wang, B.7, Chand, V.7, Groen, H.8
Source: International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS39-S40. 1p.
Subjects: Cetuximab, Gefitinib, Lung cancer treatment, Metastasis, Skin inflammation, Medical statistics
Database: Engineering Source
Description
ISSN:03603016
DOI:10.1016/j.ijrobp.2014.08.220